

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## FRONTAGE HOLDINGS CORPORATION

方達控股公司\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1521)**

### CHANGE OF CHIEF FINANCIAL OFFICER

The Board announces that with effect from July 15, 2025:

- (i) Mr. Jun (Henry) Gao will resign as the chief financial officer of the Company; and
- (ii) Ms. Huan Wang will be appointed as the interim chief financial officer of the Company.

### RESIGNATION OF CHIEF FINANCIAL OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Frontage Holdings Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Jun (Henry) Gao (“**Mr. Gao**”) has tendered his resignation and will resign as the chief financial officer (“**CFO**”) of the Company due to his other professional endeavors with effect from July 15, 2025. Mr. Gao has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation which needs to be brought to the attention of the shareholders of the Company.

The Board wishes to express its appreciation to Mr. Gao for his valuable contribution to the Company during his tenure of office as the CFO of the Company.

### APPOINTMENT OF INTERIM CHIEF FINANCIAL OFFICERS

The Board is pleased to announce that with effect from July 15, 2025, Ms. Huan Wang (“**Ms. Wang**”), currently the Vice President Finance of the Company’s wholly owned subsidiary, Frontage Laboratories, Inc. (“**Frontage Labs**”), has been appointed as interim CFO of the Company. The biographical details of Ms. Wang are as follows:

Ms. Wang, aged 40, will be responsible for the management of the Group’s finance and treasury matters. Ms. Wang has nearly two decades of experience in accounting, budgeting, and financial operations, primarily in the pharmaceutical and contract research organization (CRO) industry.

Ms. Wang joined the Group in August 2008 as a senior budget analyst and subsequently held various finance positions. She currently serves as Vice President Finance of Frontage Labs, overseeing financial planning and analysis, internal controls, and financial reporting. Ms. Wang also participated in the Company’s initial public offering in 2019.

Ms. Wang held a bachelor’s degree in international trade and economics from Beijing Wuzi University and a master’s degree of science in Administration, with a concentration in International Business, from Central Michigan University.

The Board would like to extend its welcome to Ms. Wang on her new appointment.

By Order of the Board  
**Frontage Holdings Corporation**  
**Dr. Song Li**  
*Chairman*

Hong Kong, July 14, 2025

*As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.*

\* *For identification purpose only*